VIR Vir Biotechnology Inc

Price (delayed)

$42.40

Market cap

$5.51B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.11

Enterprise value

$5.05B

Sector: Healthcare
Industry: Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are ...

Highlights

Vir Biotechnology's equity has soared by 71% YoY but it has decreased by 9% from the previous quarter
The EPS has declined by 24% since the previous quarter but it rose by 2.2% year-on-year
The net income has dropped by 75% year-on-year and by 31% since the previous quarter
VIR's quick ratio has dropped by 68% since the previous quarter and by 63% year-on-year

Key stats

What are the main financial stats of VIR
Market
Shares outstanding
130.04M
Market cap
$5.51B
Enterprise value
$5.05B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.33
Price to sales (P/S)
74.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69.54
Earnings
Revenue
$72.63M
EBIT
-$390.1M
EBITDA
-$380.53M
Free cash flow
-$237.98M
Per share
EPS
-$3.11
Free cash flow per share
-$1.86
Book value per share
$5.09
Revenue per share
$0.57
TBVPS
$8.49
Balance sheet
Total assets
$1.14B
Total liabilities
$484.63M
Debt
$66.62M
Equity
$650.95M
Working capital
$632.02M
Liquidity
Debt to equity
0.1
Current ratio
2.75
Quick ratio
2.37
Net debt/EBITDA
1.22
Margins
EBITDA margin
-524%
Gross margin
100%
Net margin
-537.5%
Operating margin
-528.3%
Efficiency
Return on assets
-42.5%
Return on equity
-56.9%
Return on invested capital
-129.8%
Return on capital employed
-50.4%
Return on sales
-537.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIR stock price

How has the Vir Biotechnology stock price performed over time
Intraday
7.21%
1 week
-1.33%
1 month
-6.92%
1 year
36.12%
YTD
58.33%
QTD
-17.3%

Financial performance

How have Vir Biotechnology's revenue and profit performed over time
Revenue
$72.63M
Gross profit
$72.63M
Operating income
-$383.7M
Net income
-$390.34M
Gross margin
100%
Net margin
-537.5%
The net margin has soared by 76% YoY but it has contracted by 37% from the previous quarter
The company's operating margin has surged by 76% YoY but it fell by 36% QoQ
The company's operating income has shrunk by 75% YoY and by 29% QoQ
The net income has dropped by 75% year-on-year and by 31% since the previous quarter

Growth

What is Vir Biotechnology's growth rate over time

Valuation

What is Vir Biotechnology stock price valuation
P/E
N/A
P/B
8.33
P/S
74.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69.54
The EPS has declined by 24% since the previous quarter but it rose by 2.2% year-on-year
Vir Biotechnology's equity has soared by 71% YoY but it has decreased by 9% from the previous quarter
VIR's price to book (P/B) is 8% higher than its last 4 quarters average of 7.2
The price to sales (P/S) is 10% higher than the last 4 quarters average of 63.0
VIR's revenue is down by 4.9% from the previous quarter

Efficiency

How efficient is Vir Biotechnology business performance
The return on sales has surged by 76% year-on-year but it has declined by 37% since the previous quarter
The return on invested capital has declined by 25% since the previous quarter and by 19% year-on-year
Vir Biotechnology's return on equity has decreased by 18% QoQ but it has increased by 3.1% YoY
Vir Biotechnology's return on assets has increased by 9% YoY but it has decreased by 7% QoQ

Dividends

What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIR.

Financial health

How did Vir Biotechnology financials performed over time
Vir Biotechnology's total assets is 134% higher than its total liabilities
The company's total liabilities has surged by 140% QoQ
Vir Biotechnology's total assets has surged by 138% YoY and by 24% QoQ
The debt is 90% less than the equity
The debt to equity has soared by 150% YoY and by 11% QoQ
Vir Biotechnology's equity has soared by 71% YoY but it has decreased by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.